Group 1 - Five Continents Medical announced a share reduction plan by major shareholders, including a reduction of approximately 1.5716% of total shares by Taihu Honghui Medical Management Partnership [1] - Supervisor Zhou Lexiang plans to reduce his holdings by approximately 0.1875% of total shares [1] - Director and Secretary Pan Lanlan intends to reduce her holdings by approximately 0.1015% of total shares [1] Group 2 - Five Continents Medical's revenue composition for 2024 is entirely from the medical device industry, accounting for 100.0% [1] - The current market capitalization of Five Continents Medical is 2.9 billion yuan [1]

Group 1 - The major shareholder Taihu Honghui plans to reduce its stake in Wuzhou Medical by 1,068,705 shares, accounting for 1.5716% of the total share capital [1] - Supervisor Zhou Lexiang intends to sell 127,500 shares, representing 0.1875% of the total share capital [1] - Director Pan Lanlan plans to reduce his holdings by 69,050 shares, which is 0.1015% of the total share capital [1] Group 2 - The reason for the share reduction is personal financial planning [1] - The method of reduction will be through centralized bidding or block trading [1] - The reduction period is set for three months following the announcement [1]

2、持有公司股份 510,000 股的监事周乐翔先生计划在本减持计划公告之日 起 15 个交易日后三个月内以集中竞价方式或大宗交易方式减持公司股份 127,500 股（占公司总股本比例的 0.1875%）。 证券代码：301234 证券简称：五洲医疗 公告编号：2025-029 安徽宏宇五洲医疗器械股份有限公司 关于持有 5%以上股份股东、董事及监事 减持股份的预披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 特别提示： 1、持有安徽宏宇五洲医疗器械股份有限公司（以下简称"公司"）股份 3,562,350 股（占公司股份总数的 5.2388%）的大股东太湖宏辉医疗管理合伙企 业（有限合伙）（以下简称"太湖宏辉"）计划在本减持计划公告之日起 15 个交 易日之后三个月内以集中竞价方式或大宗交易方式减持公司股份 1,068,705 股 （占公司总股本比例的 1.5716%）。 3、持有公司股份 276,200 股的董事、董事会秘书、副总经理潘岚岚女士计 划在本减持计划公告之日起 15 个交易日后三个月内以集中竞价方式或大宗交易 方式减持公司股份 69, ...

Core Insights - The medical device sector experienced a slight increase of 0.39% on September 29, with Tianzhihang leading the gains [1] - The Shanghai Composite Index closed at 3862.53, up 0.9%, while the Shenzhen Component Index closed at 13479.43, up 2.05% [1] Medical Device Sector Performance - Tianzhihang (688277) saw a closing price of 18.47, with a rise of 7.70% and a trading volume of 172,400 shares, amounting to a transaction value of 315 million yuan [1] - Jimin Health (603222) closed at 11.30, up 5.51%, with a trading volume of 494,600 shares and a transaction value of 556 million yuan [1] - Dongxing Medical (301290) closed at 29.32, increasing by 4.86%, with a trading volume of 99,500 shares and a transaction value of 29.67 million yuan [1] - Other notable performers included Sainuo Medical (688108) with a 4.82% increase and a closing price of 27.83, and Tianchen Medical (688013) with a 3.89% increase, closing at 59.52 [1] Capital Flow Analysis - The medical device sector saw a net inflow of 85.63 million yuan from institutional investors, while retail investors contributed a net inflow of 46.52 million yuan [2] - However, speculative funds experienced a net outflow of 132 million yuan [2] Individual Stock Capital Flow - Sainuo Medical (688108) had a net inflow of 111 million yuan from institutional investors, but a net outflow of 68.66 million yuan from speculative funds [3] - Mairui Medical (300760) also saw a significant net inflow of 107 million yuan from institutional investors, with a net outflow of 76.49 million yuan from speculative funds [3] - Jimin Health (603222) had a net inflow of 53.49 million yuan from institutional investors, while speculative funds saw a net outflow of 43.40 million yuan [3]

Company Overview - Wuzhou Medical, established on April 15, 2011, is located in Anqing City, Anhui Province, and specializes in the research, production, and sales of disposable sterile infusion medical devices and related medical supplies [1] - The company went public on July 5, 2022, and has a current market capitalization of 3.281 billion yuan [1] - Main business revenue composition includes: syringes 41.29%, medical puncture needles 25.51%, infusion and blood transfusion devices 20.92%, and others 12.28% [1] Stock Performance - On September 19, Wuzhou Medical's stock rose by 5.21%, reaching 48.25 yuan per share, with a trading volume of 60.1834 million yuan and a turnover rate of 1.91% [1] Shareholder Information - Noan Fund's Noan Multi-Strategy Mixed A (320016) is among the top ten circulating shareholders of Wuzhou Medical, having increased its holdings by 181,600 shares in the second quarter, totaling 327,900 shares, which represents 1.78% of the circulating shares [2] - The fund has achieved a year-to-date return of 59.64% and a one-year return of 124.24% [2] Fund Management - The fund manager of Noan Multi-Strategy Mixed A is Kong Xianzheng, who has been in the position for 4 years and 298 days, with a total fund asset size of 4.607 billion yuan [3] - The best and worst fund returns during Kong's tenure are 77.68% and -16.74%, respectively [3] - Co-manager Wang Haichang has been in the role for 3 years and 60 days, managing assets of 2.529 billion yuan, with best and worst returns of 65.18% and -18.8% [3]

Group 1: Company Development Plans - The company focuses on the field of single-use sterile infusion medical consumables, including innovations in syringes, infusion and blood transfusion devices, and medical puncture needles [1][2] - The company aims to deepen technological innovation and expand market channels to establish a solid foundation for high-quality and sustainable development [1][2] Group 2: Investor Engagement - The investor relations activity was conducted via an online platform on September 15, 2025, from 14:00 to 17:00 [1] - The company expressed gratitude for investor support and emphasized the importance of referring to official disclosures for significant company matters [2]

Company Overview - Wuzhou Medical, established on April 15, 2011, is located in Taihu County, Anqing City, Anhui Province, and was listed on July 5, 2022 [1] - The company specializes in the research, production, and sales of disposable sterile infusion medical devices and other related medical supplies, primarily using an "ODM + integrated supply" model to meet the one-stop procurement needs of foreign medical device brand companies [1] - The main revenue composition includes: syringes 41.29%, medical puncture needles 25.51%, infusion and blood transfusion devices 20.92%, and others 12.28% [1] Stock Performance - On September 12, Wuzhou Medical's stock rose by 5.24%, reaching a price of 48.64 CNY per share, with a trading volume of 56.6895 million CNY and a turnover rate of 1.76%, resulting in a total market capitalization of 3.308 billion CNY [1] Shareholder Information - Noan Fund's Noan Multi-Strategy Mixed A (320016) fund is among the top ten circulating shareholders of Wuzhou Medical, having increased its holdings by 181,600 shares in the second quarter, totaling 327,900 shares, which represents 1.78% of the circulating shares [2] - The fund has achieved a year-to-date return of 61.81%, ranking 429 out of 8,174 in its category, and a one-year return of 121.96%, ranking 230 out of 7,981 [2]

Core Viewpoint - Anhui Hongyu Wuzhou Medical Devices Co., Ltd. is participating in the "2025 Anhui Listed Companies Investor Online Collective Reception Day" to enhance interaction with investors [1][2] Group 1: Event Details - The event will be held online on September 15, 2025, from 15:00 to 17:00 [1] - Investors can participate through the "Panjing Roadshow" website, WeChat public account, or by downloading the Panjing Roadshow APP [1] Group 2: Topics of Discussion - The company will address various investor concerns, including company performance, governance, development strategy, operational status, financing plans, equity incentives, and sustainable development [1]

光大证券股份有限公司关于安徽宏宇五洲医疗器械股份有限公司 2025年半年度持续督导跟踪报告 | 保荐机构名称：光大证券股份有限公司 | 被保荐公司简称：五洲医疗 | | --- | --- | | 保荐代表人姓名：黄腾飞 | 联系电话：021-22169999 | | 保荐代表人姓名：林剑云 | 联系电话：021-22169999 | 一、保荐工作概述 1 | （1）发表专项意见次数 | 次 2 | | --- | --- | | （2）发表非同意意见所涉问题及结论意见 | 无 | | 7.向本所报告情况（现场检查报告除外） | | | （1）向本所报告的次数 | 次 0 | | （2）报告事项的主要内容 | 不适用 | | （3）报告事项的进展或者整改情况 | 不适用 | | 8．关注职责的履行情况 | | | （1）是否存在需要关注的事项 | 无 | | （2）关注事项的主要内容 | 不适用 | | （3）关注事项的进展或者整改情况 | 不适用 | | 9.保荐业务工作底稿记录、保管是否合规 | 是 | | 10.对上市公司培训情况 | | | （1）培训次数 | 次 0 | | （2）培训日期 | 不适 ...

证券代码：301234 证券简称：五洲医疗 公告编号：2025-028 公司本次活动采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP 参与本次互动交流，活动时间为 2025 年 9 月 15 日（星期一）15:00-17:00。届 时公司将在线就公司业绩、公司治理、发展战略、经营状况、融资计划、股权激 励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资 者踊跃参与。 特此公告。 安徽宏宇五洲医疗器械股份有限公司 二〇二五年九月九日 安徽宏宇五洲医疗器械股份有限公司 关于参加 2025 年安徽辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 为进一步加强与投资者的互动交流，安徽宏宇五洲医疗器械股份有限公司 （以下简称"公司"）将参加由安徽证监局指导，安徽上市公司协会与深圳市全 景网络有限公司联合举办的"2025 年安徽上市公司投资者网上集体接待日"活 动，现将相关事项公告如下： ...